The Roskamp Institute, Inc.

The Roskamp Institute, Inc., a tax-exempt non-profit biotechnology research organization headquartered in Sarasota, Florida, operates as a federal grant recipient and contract performer in neuroscience research, specializing in preclinical investigations of traumatic brain injury, Alzheimer's disease, Gulf War Illness, and organophosphate neurotoxicity.

The institute competes on full-and-open solicitations without set-aside designations. It holds a diversified portfolio spanning 78 awards across contracts and grants, with 96% prime participation. Customer concentration runs heavily toward the Department of Veterans Affairs Veterans Integrated Service Network 8 (21 awards, $4.2 million combined potential value), the Defense Health Agency (20 awards, no dollar ceiling specified in the source), the National Institute on Aging (15 awards), and the Army Medical Command (11 awards). The institute holds single-award indefinite delivery contracts with VISN 8 for animal research support and veterinary maintenance services, with ceilings of $260,260 and $222,000 respectively, executing task orders through September 2026 and September 2029.

The grant portfolio dominates recent activity. Defense Health Agency awards under CFDA 12.420 (Military Medical Research and Development) total roughly $7.9 million across multiple concurrent projects: a $3.27 million award (September 2025 through September 2029) investigating novel blood-brain-barrier-penetrable peroxisome proliferator-activated receptor agonists for age-related repetitive mild traumatic brain injury; a $1.633 million award (June 2024 through June 2028) developing ultraselective DYRK1A inhibitors for traumatic brain injury; additional awards addressing microglial inflammasome activation, PTEN signaling in chronic TBI sequelae, and amnion-derived cell therapies for both Gulf War Illness and traumatic brain injury. National Institute on Aging awards under CFDA 93.866 (Aging Research) and related programs total roughly $2.5 million across concurrent projects examining microglial PPARG activation following repetitive mild TBI, APOE4-mediated brain bioenergetics deficits, and cerebrovascular contributions to Alzheimer's disease pathology. Additional work includes a $468,875 Trans-NIH Research Support award (CFDA 93.310) from the National Institute on Aging investigating oleoylethanolamide as a medical countermeasure for organophosphate neurotoxicity, and a $2.2 million National Institute of Environmental Health Sciences award examining neurological effects of aerosolized red tide neurotoxins in Gulf Coast populations.

Activity has grown from seven awards in 2022 to eleven in 2024, with three awards in 2025 and two in 2026, though the trajectory shows recent flattening. Eleven awards (combined potential value $80 thousand) reach ultimate completion within the next twenty-four months, representing modest recompete exposure. On VA contracts, the institute provides animal research support services and critical-function veterinary maintenance services in Tampa, Florida, with place of performance extending through option periods running into 2030. The institute subcontracts as a named sub on two university grants: co-investigator metabolomics and lipidomics work on a Gulf War Illness study under Boston University (November 2024) and cognitive training research on older adult impairment under the University of South Florida (December 2023 and November 2024). Service Contract Inventory reporting captures minimal activity — zero prime SCI records and two SCI subcontractor records spanning FY2022–FY2024, reflecting roughly 3.9 FTEs on named federal service contracts above the $150,000 threshold in FY2024, suggesting the institute's federal revenue flows predominantly through grant mechanisms rather than labor-hour service contracts.